TEST:

Signatera™

Are you using ctDNA MRD assays like Signatera for your patients with early stage #breastcancer ? But Medicare is covering Signatra. I have NO conflict 😀 (@jamecancerdoc)

What type of ctDNA assays do you like to use here? Is there a Signatera-like/tissue-informed choice in #urothelialcarcinoma, or just a general cell-free DNA approach? #TumorBoardTuesday I imagine this could also be really interesting when treating FGFR fusions w targeted agents. (@JohnEbbenMDPhD)

Great story highlighting the potential of liquid biopsy to detect #colorectalcancer recurrence in patients with early stage disease using Signatera from @NateraGenetics. @skopetz killing it as usual. (@jonmizrahi)

$NTRA New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma https://t.co/MJ9IxREVsU (@stock_titan)

Join me and @HKennecke as we break down the latest Signatera #ctdna data in GI malignancies with real world examples straight from the clinic. 🧬🧬 (@OncoJurdi)

Wonderful poster walk session @alantanmd #GU23 featuring work with ctDNA and Signatera ! Much more to come! We learned so much! @ASCO ()

Signatera data from @arnabguonc, @alantanmd and @LDyrskjot was featured in the #MIBC and #RCC poster walks at #ASCOGU23. Productive #GU23 meeting for #TeamNatera! @OlgaAlexeeva16 @BlkBoiScientist @MarkCalhoun_ @CarciaCarson @npajakMSL @ShrutiS97567202 ()

How can #Signatera #ctDNA help treatment decisions in #RCC? Watch @arnabguonc answer @CParkMD's questions about new data from #ASCOGU23 #GU23 ()

Does #KidneyCancer shed detectable #ctDNA? Watch @tompowles1 interview @arnabguonc on his 45 patient poster with @alantanmd in #mRCC #Signatera #ASCOGU23 #GU23 ()

What an honor to have Dr. @tompowles1 come by and review our Signatera poster with @PBarataMD and hardworking folks at @NateraGenetics at @ASCO #GU23! Big fan of @Uromigos! @CParkMD @brian_rini @JasonBrownMDPhD @koshkin85 @AmandaNizamMD @TulaneDDoM ()

Medicare Extends Coverage of Natera’s Signatera MRD Test to Breast Cancer https://t.co/pCTV0IMTuA ()

@CathyEngMD @Latinamd @GIOncologist @WuGiOnc @HaoXieMDPhD @alshamsi2000 @UaeEma @SocietyEmirates #WorldGI20 @myESMO @NateraOncology #SignateraLooksDeeper @ShankaranVeena @SKamath_MD @NDeVitoMD @MissSheriMD @KimmieNgMD @DrKelseyKlute @rachnatshroff ()

Signatera #ctDNA in Anal Cancer presented by Dr Janet Alvarez of @MSKCancerCenter. Early and reliable response assessment. 100 days on average before traditional restaging methods. @JoshSmithMDPhD ()

#ctDNA kinetics using @NateraOncology Signatera on St I-III #crcsm (60% had 1st draw 0-12 wks postop). Higher cfDNA conc in 2-4 wks and highest ctDNA+ in 1st 2 wks but cfDNA does not impact ctDNA detection. Could send for ctDNA as soon as 2 wks post-op? #GI23 @OncoAlert ()

CIRCULATE-Japan @NatureMedicine, seeking MRD (Signatera @NateraOncology ) guided optimal adjuvant treatment in CRC patients. Looking forward to checking more data on thoracic malignancies especially NSCLC with or without EGFR mutation. https://t.co/j5PRM6gjWb ()

1b Er/Pr+ #breastcancer w/+ #ctDNA #MRD via #signatera. Tagging ppl assoc w/these #’s to share my experience @JAMAOnc @hthrparsons @FilippoMontemu1 @CarlosHBarcenas @stolaney1 @ArielleMedford @nlinmd @aaleshin @NCIDirector @maryam_lustberg @Dr_RShatsky @DanaFarber @HillStirSci ()

🔥ctDNA to predict risk of recurrence in esophagogastric cancer 🔥 @JCOPO_ASCO https://t.co/NmGrUjVE2n ✅🇺🇸RWD 295pts 🔎Signatera/16 pt specific SNVs -> ctDNA pos.: 👉pre-OP: 96% 👉post-OP: 23% -> strongly associated with RFS 👏Helpful for risk stratification @myESMO @OncoAlert ()

@skopetz hello sir I’m stage 4 colon cancer chemo didn’t work I have the braf v600e mutation I started keytruda 3 months ago and just got my signatera results back and they are now negative do you recommend I be taking anything else with this. Thanks ()

I just finished treatment for stage 1 HR+ breast cancer.Did great w/all treatments & all scans clear.Did #signatera testing to monitor for recurrence, thinking I would get a head start on treatment in event of recurrence.First test positive (!) but there is no approved treatment! ()

Personalized, ctDNA analysis to detect minimal residual disease & identify Pts at high risk of relapse w/ multiple myeloma - @bhemato et al. @Phari #ASCO21 Abstract 8029 https://t.co/OyywlExqea #mmsm #mmMRD n=28 BM flow vs @NateraOncology Signatera MRD @ 3 months post-AHCT ()

@NateraOncology Signatera™ tumor-informed minimal residual disease (MRD) #ctDNA test to select patients with Muscle-Invasive #bladdercancer for adjuvant therapy-results of twitter #poll regarding use by physicians @OncoAlert @practiceupdate @BladderCancerUS: https://t.co/cP0ckth4U0 ()

@NateraOncology Signatera™ tumor-informed minimal residual disease (MRD) #ctDNA test to select patients with Muscle-Invasive #bladdercancer for adjuvant therapy-results of twitter #poll regarding use by physicians @OncoAlert @practiceupdate @BladderCancerUS ()

@NateraOncology Signatera™ tumor-informed minimal residual disease (MRD) #ctDNA test to select patients with Muscle-Invasive #bladdercancer for adjuvant therapy-results of twitter #poll regarding use by physicians @OncoAlert @practiceupdate @BladderCancerUS : ()

Medicare extended coverage of @NateraOncology Signatera™ minimal residual disease (MRD) #ctDNA test to Muscle-Invasive #bladdercancer on July 18, 22 @oncolaert @practiceupdate @BladderCancerUS @tompowles1 @MattGalsky; I will use test to select patients for adjuvant therapy in: ()

Medicare Extends Coverage of Natera's Signatera™ MRD Test to Muscle Invasive #bladdercancer. https://t.co/E8PfZADBoe via @Yahoo @MattGalsky with @IcahnMountSinai comments ()

We have activated CIRCULATE-US (NRG-GI008) @Perlmutter_CC & @NYULISOM_HemOnc looking at escalation and descalation stratgies in adjuvant #crcsm patients using @NateraOncology SIGNATERA assay! Primary populations: low risk Stg III patients and ctDNA+ Stg II + IIIC ()

@CathyEngMD @Latinamd @GIOncologist @WuGiOnc @HaoXieMDPhD @alshamsi2000 @UaeEma @SocietyEmirates #WorldGI20 @myESMO @NateraOncology #SignateraLooksDeeper ()

The problem is that this surveillance protocol is already outdated. The best way to screen people like this and others who have bad genes is going to be through cell free DNA, just like the Guardant/Signatera strategy already in use in colon cancer ()

Honored to have my poster selected as the best one in the advanced kidney cancer moderated poster session! Grateful for the mentorship of @PBarataMD and excited for the opportunities to network! #Natera #Signatera #AUA22 ()

How reliable is signatera testing for pancreatic cancer? I just got a negative result! ()

@SanoMedCenter large obs cohort CIRCULATE-Japan resected st II-IV #crcsm #Signatera ctDNA post-op 4W ctDNA- approx 97% #DFS rate, in post-op ctDNA+ adj chemo (ACT) cleared #ctDNA w/improved DFS, in post-op 4W ctDNA- no DFS difference b/t ACT vs no ACT #gi22 ()

@CathyEngMD @Latinamd @GIOncologist @WuGiOnc @HaoXieMDPhD @alshamsi2000 @UaeEma @SocietyEmirates #WorldGI20 @myESMO @NateraOncology #SignateraLooksDeeper @ShankaranVeena @SKamath_MD @NDeVitoMD @MissSheriMD @KimmieNgMD @DrKelseyKlute @rachnatshroff ()

@CathyEngMD @Latinamd @GIOncologist @WuGiOnc @HaoXieMDPhD @alshamsi2000 @UaeEma @SocietyEmirates #WorldGI20 @myESMO @NateraOncology #SignateraLooksDeeper @ShankaranVeena @SKamath_MD @NDeVitoMD @MissSheriMD @KimmieNgMD @DrKelseyKlute @rachnatshroff ()

@CathyEngMD @Latinamd @GIOncologist @WuGiOnc @HaoXieMDPhD @alshamsi2000 @UaeEma @SocietyEmirates #WorldGI20 @myESMO @NateraOncology #SignateraLooksDeeper @ShankaranVeena @SKamath_MD @NDeVitoMD @MissSheriMD @KimmieNgMD @DrKelseyKlute @rachnatshroff ()

Join me along with @gregorybotta @doctorC369 as we review the latest #signatera #ctdna data in GI malignancies and how to apply it in clinic. ()

@RonaYaeger breaks down obs GALAXY in CIRCULATE-Japan of Signatera tumor-informed ctDNA platform = strong prognostic marker in large non-randomized data, needs prospective validation of ctDNA actionability, ongoing trials of Tx escalation vs deescalation #CNRealtimeReport #GI22 (@CancerNetwrk)

OK..Thanks! If Signatera turns positive later, start chemo then? In ppl not exposed to adj chemo, even if #ctDNA +, seems to benefit if chemo started later when ctDNA+? #GI22 @ASCO #CRCSM (@manjuggm)

Personally, I send ctDNA (signatera) AND immunoscore for patients with stage II colon cancer and don't recommend adjuvant unless ctDNA+ or immunoscore low (@benweinbergmd)

@CathyEngMD @Latinamd @GIOncologist @WuGiOnc @HaoXieMDPhD @alshamsi2000 @UaeEma @SocietyEmirates #WorldGI20 @myESMO @NateraOncology #SignateraLooksDeeper @ShankaranVeena @SKamath_MD @NDeVitoMD @MissSheriMD @KimmieNgMD @DrKelseyKlute @rachnatshroff (@MaenAbdelrahim)

https://t.co/6vd65auy8p Presenting comparative data today on Signatera versus imaging studies in curatively resected colorectal cancer. Not enough data yet to confirm clinical utility of Signatera in surveillance (@mgfakih)

35 year old man p/w LLQ abd pain, wt loss, found to have pT3pN0 sigmoid colon cancer w/o high risk features, MSI-H ➡️ no adjuvant therapy recommended, but ctDNA (Signatera) is ordered... (@benweinbergmd)

@CathyEngMD @Latinamd @GIOncologist @WuGiOnc @HaoXieMDPhD @alshamsi2000 @UaeEma @SocietyEmirates #WorldGI20 @myESMO @NateraOncology #SignateraLooksDeeper @ShankaranVeena @SKamath_MD @NDeVitoMD @MissSheriMD @KimmieNgMD @DrKelseyKlute @rachnatshroff (@MaenAbdelrahim)